Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of CDP870 400 mg in Combination With Methotrexate Compared to Methotrexate Alone in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Are Partial Responders to Methotrexate

NCT00544154 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00544154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00544154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of CDP870 400 mg in Combination With Methotrexate Compared to Methotrexate Alone in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Are Partial Responders to Methotrexate
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2002
Completion date
January 31, 2004
Enrollment
247 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid